Literature DB >> 25325148

Genotypic Detection of Epstein Barr Virus from Clinically Suspected Viral Retinitis Patients in a Tertiary Eye Care Centre, India.

Madhuravasal Krishnan Janani1, Jambulingam Malathi1, Jyothirmay Biswas1, Sudharshan Sridharan1, Hajib Naraharirao Madhavan1.   

Abstract

PURPOSE: To evaluate the diagnostic value of PCR on aqueous humour for detection and genotyping of Epstein Bar Virus in patients with viral retinitis.
METHODS: 70 AH samples were collected from 20 HIV positive patients with clinically suspected viral retinitis and 25 patients with serpignous choroiditis and 25 AH from patients undergoing cataract surgery. PCR was performed to screen HHV-1 to HHV-5, Mtb and Toxoplasma gondii. Genotype prevalence was confirmed by phylogenetic analysis targetig EBV.
RESULTS: EBV was detected in 17 (37.7%) samples. Genotyping to subtype EBV, revealed the circulation of only one subtype (Type 1). PCR results for other infective agents were negative except for the presence of CMV in 5 (11.1%) AH.
CONCLUSION: The application of PCR to detect genotypes can be used as an epidemiological tool for clinical management. To our knowledge this is the first report on genotyping of EBV performed on intra ocular samples.

Entities:  

Keywords:  Detection; Epstein-Barr virus; PCR; genotyping; viral retinitis

Mesh:

Substances:

Year:  2014        PMID: 25325148     DOI: 10.3109/09273948.2014.968265

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  2 in total

1.  Lyme Borrelia as the etiological factor in three cases of primary inflammatory choriocapillaropathies.

Authors:  Svetlana V Jovanovic; Nenad T Petrovic; Maja Lj Zivkovic; Zorica G Toncic; Tatjana S Sarenac Vulovic
Journal:  Int J Ophthalmol       Date:  2017-12-18       Impact factor: 1.779

2.  Retinitis as the presenting feature of subacute sclerosing panencephalitis in an Indian male: A case report.

Authors:  Amravi Shah; Rajesh Babu; Jyotirmoy Biswas
Journal:  Indian J Ophthalmol       Date:  2018-10       Impact factor: 1.848

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.